Question to Merck CEO Regarding Merck's Continuing Support for ObamaCare

National Center for Public Policy Research Vice President David Ridenour asks Merck CEO Kenneth Frazier 1) if he will commit to sharing with Merck shareholders the amount of money Merck spent through PhRMA pushing for passage of ObamaCare, and 2) if Merck is rethinking its support for ObamaCare now that an FOIA request has revealed that the Centers for Medicaid and Medicare's recent review of the prostate cancer drug, Provenge, appears to have been prompted, at least in part, by concerns over costs. Frazier refused to commit to making available to shareholders the amount Merck spent promoting the passage of ObamaCare, saying only that he would take the suggestion "under advisement." On the question of support for ObamaCare, Frazier praised the legislation, saying it would expand health care coverage by 32 million people. This question-and-answer was part of the 2011 Merck shareholder meeting on May 24, 2011 in North Branch, New Jersey. www.nationalcenter.org http
merck obamacare health care shareholder meeting kenneth frazier david ridenour Sunny Day America


























